跳至主要内容
临床试验/IRCT20180620040164N35
IRCT20180620040164N35已完成未知

Comparative bioequivalence study of Betahistine 16 mg tablet of ACTOVERCO and Abbott in 24 healthy male under fasting

Actover Pharmaceutical Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 45 years(—)
性别
Male

入选标准

  • Healthy subjects (male) between 20 – 45 years of age and Body Mass Index (BMI) within 15% of normal range according to the accepted normal values between 18.5 and 30 (inclusive), calculated as kg/m2.
  • Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
  • Subjects with normal vital signs.
  • Subjects who agree with patient consent form.

排除标准

  • Subjects with known allergy to the products tested.
  • Smoking more than 10 cigarettes per day and could not tolerate cigarette cessation during each clinical period.
  • Subjects who has used any drug including prescription or Over-The-Counter (OTC) drugs within 7 days prior to the start of the study and might need drug intake during study period.
  • History of alcohol or drug abuse within 2 years before the start of the study.
  • Heavy drinker of caffeine, grapefruit juice or caffeinated drinks or who are on special diet (such as vegetarians) or do exertional physical activity.
  • A history of difficulty with donating blood or donation of more than 500 ml blood within 7 days prior to the start of the study.

研究者

发起方
Actover Pharmaceutical Co.

相似试验